期刊文献+

应用蒙特卡罗模拟优化肾功能不全患者肠球菌感染时万古霉素的给药方案 被引量:4

Use of Monte Carlo simulation method to optimize dosing regimens for vancomycin in patients with renal insufficiency with enterococcal infections
原文传递
导出
摘要 目的:根据抗菌药物PK/PD理论,采用蒙特卡罗模拟的手段,对肾功能不全患者万古霉素治疗肠球菌感染的给药方案进行优化。方法:收集已发表的万古霉素的药动学资料和我院万古霉素对粪肠球菌和屎肠球菌的MIC分布数据;设置AUC24h/MIC>400,利用Crystal Ball软件模拟出5 000个患者的PTA和CFR。结果:万古霉素能达到满意抗菌活性的最低剂量:对于肌酐清除率>80 mL.min-1的患者(A组),当MIC=0.5μg.mL-1时,给予万古霉素1 500 mg.d-1;当MIC=1μg.mL-1时,给予万古霉素2 500 mg.d-1。对于肌酐清除率在50~80 mL.min-1的患者,当MIC=0.5μg.mL-1时,给予万古霉素1 000 mg.d-1,当MIC=1μg.mL-1时,给予万古霉素2 000 mg.d-1。对于肌酐清除率在10~50 mL.min-1的患者,只有在MIC=0.5μg.mL-1时给予750 mg.d-1,才能达到满意的抗菌活性。结论:蒙特卡罗模拟法把药动学和药效学结合起来,既考虑了不同个体对药物处置的差异性,又考虑了病原菌耐药性的差异,这样获得的给药方案将更合理,也更能提高临床治疗效果。 OBJECTIVE According to the antibiotic PK/PD theory, and adopting Monte Carlo simulation method, to optimize the drug administration scheme in patients with renal insufficiency treated with vancomycin against enterococcus infection. METHODS The published pharmacokinetic data of vancomycin and the MIC data distribution in our hospital about vancomycin against Enterococcus faecalis and Enterococcus faecium were collected; setting AUC24 h/MIC〉400, and using Crystal Ball software to simulate 5 000 patients with PTA and CFR. RESULTS at the lowest dose: for the patients with creatinine clearance 〉 80 Vancomycin could achieve satisfactory antibacterial activity mL-min 1 (group A), when MIC= 0. 5 μg·mL^-1, giving vancomycin 1 500 ·d^-1 when MIC= 1 μg·mL^-1, giving vancomycin 2 500 mg·d^-1. For the patients with creatinine clearance rate in 50-80 mL·mai^-1 , when MIC= 0. 5 μg·mL^-1, vancomycin was given with 1 000 mg; when MIC= 1 μg·mL^-1 , giving vancomycin 2 000 ·d^-1. For the patients with creatinine clearance rate in 10-50 mL·min^-1, only in MIC = 0. 5μg·mL^-1 vancomycin given at the dose of 750 mg· d^-1 could achieve a satisfactory antibacterial activity. CONCLUSION The Monte Carlo simulation method combined pharmacokinetics with pharmacodynamics, considering not only the difference of drug disposition in different individuals, but also the difference in drug resistance of pathogenic bacteria, so the acquired dosing regimens will be more reasonable, and can be used for improving the effect of clinical treatment.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2012年第8期600-603,共4页 Chinese Journal of Hospital Pharmacy
关键词 蒙特卡罗模拟法 万古霉素 肌酐清除率 肠球菌感染 药动学 药效学 Monte Carlo simulation method vancomycin creatinine clearance rate enterococcus infection pharmacokinetics pharmacodynamics
  • 相关文献

参考文献6

  • 1陈新谦.新编药物学[M]北京:人民卫生出版社,200793.
  • 2Mouton JW,Dudley MN,Cars O. Standardization of pharmacokinetic/pharmacodynamic(PK/PD) terminology for antinfective drugs:an update[J].Journal of Antimicrobial Chemotherapy,2005,(05):601-607.
  • 3史军.药物动力学和药效动力学在抗菌药物新药开发和临床治疗上的应用[J].中国临床药理学与治疗学,2007,12(2):121-133. 被引量:34
  • 4季闽春,沈晓英,杨耀芳.万古霉素的药代动力学研究进展[J].中国临床药理学杂志,2008,24(6):529-532. 被引量:29
  • 5Hyatt JM,McKirnon PS,Zimmer GS. The importance of pharmacokinetic pharmacodynamic surrogate markers to outcome[J].Clinical Pharmacokinetics,1995.143-160.
  • 6Maria MF,Dolores Santos B,Amparo SN. Vancomycin Dosage Optimization in Patients with Malignant Haematological Disease by Pharmacokinetic/Pharmacodynamic Analysis[J].Clinical Pharmacokinetics,2009,(04):273-280.

二级参考文献52

  • 1Rybak MJ . The pharmacokinetic and pharmacodynamic properties of vancomycin [ J ] . Clin Infect Dis, 2006 ;42 ( Suppl. ) : S35 -S39.
  • 2Laiprasert J, Klein K, Mueller BA, et al. Transplacental passage of vancomycin in noninfected term pregnant women [ J ]. Obstet Gynecol, 2007; 109:1105-1110.
  • 3de Jesu's Valle M J, Lo'pez FG, Hurle AD, et al. Pulmonary versus systemic delivery of antibiotics: comparison of vancomycin dispositions in the isolated rat lung [ J ]. Antimicrob Agents Chemother, 2007 ; 51 : 3771 - 3774.
  • 4Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic pharmacodynamic surrogate markers to outcome [J]. Clin Pharmacokinet, 1995 ;28 : 143 - 160.
  • 5Hermsen ED. Pharmacokinetic Training packet for Pharmacists [DB/OL]. http ://intranet. nebraskamed. com/careers/education/asp/pdfs/ pk - training packet, pdf. ,2007 - 09 - 12.
  • 6Duffull SB , Begg EJ, Chambers S T,et al. Efficacies of different van- comycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model[ J ]. Antimicrob Agents Chemother, 1994 ; 38 : 2480 - 2482.
  • 7Jeffres MN , Isakow W, Doherty JA, et al. Predictors of mortality for methicillin - resistant Staphylococcus aureus health - care - associated Pneumonia: specific evaluation of vancomycin pharmacokinetic indices [ J ]. Chest, 2006 ; 130:947 - 955.
  • 8Wang JT, Fang CT, Chen YC. Necessity of a loading dose when using vancomycin in critically ill patients [ J ]. J Antimicrob Chemother, 2001 ;47 : 246.
  • 9Jeffres N , Isakow W, Doherty JA ,et al. A retrospective analysis of pos- sible renal toxicity associated with vancomycin in patients with health care - associated methicillin - resistant Staphylococcus aureus Pneumonia[J]. Clin Ther, 2007;29:1107 - 1115.
  • 10Lucksiri A, Scott MK, Mueller BA, et al. CAHP - 210 dialyzer influence on intra -dialytic vancomycin removal [ J ]. Nephrol Dial Transplant, 2002; 17:1649 - 1654.

共引文献60

同被引文献34

引证文献4

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部